You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Ambry will provide RNA sequencing for Scipher's PrismRA blood test to predict response to TNF inhibitor therapies in rheumatoid arthritis patients.
The gene expression test retrospectively identified rheumatoid arthritis patients significantly less likely to respond to TNF inhibitor therapy.
A pre-flare-up transcriptional profile in the blood led the team to a group of "pre-inflammation mesenchymal," or PRIME, cells in rheumatoid arthritis.
In January a federal court unsealed a False Claims Act suit from an industry insider that alleges a Myriad subsidiary engaged in a fraudulent kickback scheme.
In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.
The alliance will initially focus on rheumatoid arthritis using biomarkers discovered using Nimble's human proteome immunoprofiling technology.
The company plans to use the funds to fuel its diagnostic development work, focused on predicting drug response in various autoimmune diseases.
The company has raised $30 million to date to fund development and commercialization of its molecular diagnostic test to predict response to anti-TNF therapies.
Somalogic will use its SomaScan platform to analyze at least 15,000 clinical samples from Janssen to identify protein biomarkers for various diseases.
In PLOS this week: population genetics of region with high Burkitt lymphoma rates, analysis of Brazilian Chikungunya virus strains, and more.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.